Clinical Trial

Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated July 13, 2023 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
All participants will be tested for EBV associated biomarkers, including EBNA1-IgA, VCA-IgA, BNLF2b total antibodies (P85-Ab) et al. For all male participants and P85-Ab positive female participants, EBV DNA in plasma will be tested. Screening positive participants will be followed up annually. All subjects will also be followed by record linkage to Cancer Register and Population Register.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2019-09-09; most recent amendment 2023-07-12.
Trial Details
NCT Number NCT04085900
Lead Sponsor Zhongshan People's Hospital, Guangdong, China
Collaborators: Wuzhou Red Cross Hospital, Xiamen University
Conditions Nasopharyngeal Carcinoma
Enrollment 40,000 participants
Start Date 2020-04-01
Primary Completion 2024-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2023-07-13